Using an HPLC procedure, we evaluated >10 minor hemoglobins (Hbs) in healthy adults, individuals on longterm aspirin therapy, diabetic subjects, and uremic patients. Hb A1 and Hb Aida were the most abundant and important minor Hb components, respectively, accounting for 4.10% ± 0.50% and 3.46% ± 0.43% of total Hb in 361 healthy subjects. Acetylated Hb A was a potential interferent in the measurement of Hb A1. The amounts of both Hb Aid3 and Hb A1 were significantly increased in uremic patients, indicating that these Hb adducts may be carbamylated. There was a significant correlation (r = 0.69, P <0.0001) between the amounts of Hb A,d3 and plasma urea in uremic patients. Nonuremic subjects were clearly separated from uremic patients with regard to the Hb Aidn content of their total Hb. Our data suggest that Hb Aida is useful for assessment of the uremic state and that the combination of Hb A1 and Hb A1d3 could be well-suited for simultaneous control of carbohydrate and urea metabolism.
Using an HPLC procedure, we evaluated >10 minor hemoglobins (Hbs) in healthy adults, individuals on longterm aspirin therapy, diabetic subjects, and uremic patients. Hb A1 and Hb Aida were the most abundant and important minor Hb components, respectively, accounting for 4.10% ± 0.50% and 3.46% ± 0.43% of total Hb in 361 healthy subjects. Acetylated Hb A was a potential interferent in the measurement of Hb A1. The amounts of both Hb Aid3 and Hb A1 were significantly increased in uremic patients, indicating that these Hb adducts may be carbamylated. There was a significant correlation (r = 0.69, P <0.0001) between the amounts of Hb A,d3 and plasma urea in uremic patients. Nonuremic subjects were clearly separated from uremic patients with regard to the Hb Aidn content of their total Hb. Our data suggest that Hb Aida is useful for assessment of the uremic state and that the combination of Hb A1 and Hb A1d3 could be well-suited for simultaneous control of carbohydrate and urea metabolism. Results Figure  1 shows the separation of the minor Hbs present in erythrocyte lysate from a nondiabetic, nonuremic subject and from a nondiabetic subject on long-term aspirin intake who also abused alcohol. The
Hb A10 value of the latter subject as determined by Po1yCAT A HPLC was lower than that obtained ( Fig. 1, inset) by the HPLC method (Diamat;
Bio-Rad, Richmond, CA) in current routine use: 4.3% vs 6.3%. Fig. 2 shows the chromatogram for a sample from a diabetic patient.
The relative proportions of minor Hbs in the blood sample from subjects with chronic renal failure are illustrated in Fig. 3 . In general, the minor Hbs were designated according to the order of their elution from the column; however, the component eluting just after Hb Aibs was assigned to a carbamylated adduct of Hb A1 (Hb Ajb) and, after elimination of the labile Hb A10 (Schiff-base intermediate), the peak eluting just prior to Hb A, was designated HbAA. Samples from a normal control and a uremic diabetic patient were analyzed by affinity chromatography, and the glycated and nonglycated fractions were rechromatographed on the Po1yCAT A HPLC column. The distribution of the minor Hbs separated from glycated and nonglycated fractions is listed in Table 1 . The glycoHb fraction contained 30.69% Hb A10, 7.42% Hb Aids, and 49.20% Hb A0, similar to the components in the control sample. The respective percentages in the sample from a uremic diabetic patient were: 87.80%, 7.49%, and 45.60%. Proportions of Hb A10 and Hb A1 in the nonglycoHb fraction were significantly greater in the uremic diabetic patient than in a control: 3.51% and 5.70% vs 2.40% and 4.70%, respectively.
In erythrocyte lysates, Hb A10 and Hb A153, the most abundant minor components, were distributed among 50 normal controls and 50 uremic subjects as shown in Fig. 4 patients were divided into diabetic (n = 50) and nondiabetic (n = 50) subjects, the Hb Aids content was 5.44% ± 1.56% and 5.91% ± 0.87%, respectively. In nondiabetic uremic patients, Hb A10 was in the normal range (4.08% ± 0.60%). Normal controls and diabetic patients with normal renal function did not significantly differ with regard to Hb Aids (3.46% ± 0.43% vs 3.60% ± 0.70%).
In some chromatographic conditions, Hb Aids ap- Fig. 3B Hb AA averaged 1.00% ± 0.19% (SD) of total Hb in nondiabetic patients (n = 50) on long-term aspirin therapy and 0.88% ± 0.06% (SD) in healthy subjects (n = 40) taking aspirin regularly. Similar values were observed in diabetic patients habitually taking aspirin. The increase of this fraction was related to the amount of drug intake (e.g., acetylsalicylate or acetaminophen) or alcohol consumption, or both (Fig. 1, bottom) .
The correlation between Hb A1b patients, we expect that the a-chain is preferentially carbamylated over the a-chain. This is compatible with the observation that the p-NH2 terminus is most commonly glycated, the a-NH2 terminus being a less common site for glycation (10) . Indeed, the plasma urea concentration in uremic patients correlates significantly with Hb Aids, but not with Hb A10. This result is similar to the correlation of plasma urea concentrations with the valine hydantoin released by acid hydrolysis of carbamylated Hbs (11, 12 We also found that Hb AA accounts for 1.1% of total Hb in patients on long-term aspirin therapy. Combining alcoholism with aspirin intake may increase this fraction. As shown in Fig. 1 (inset) In conclusion, the present study provides evidence that measurement of Hb Alcarb and Hb Aids may be useful for assessing uremia, and might allow the monitoring of the diet and therapy in uremic patients.
These Hb adducts could be also used as biochemical markers for the pathogenesis of the uremic sequelae. Moreover, the method we used may allow simultaneous control of carbohydrate and urea metabolism in diabetic and nondiabetic patients with renal failure. Our data warrant further exploration through a longitudinal study in larger groups of uremic patients having different modes of dialysis treatment and various degrees of uremic exposure.
Such a study is in process and will be the subject of subsequent publication.
